期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
3种不同中药注射液治疗小儿支气管肺炎疗效比较 被引量:6
1
作者 赵素香 张永生 徐萍 《中国中西医结合儿科学》 2012年第2期137-138,共2页
目的比较炎琥宁、痰热清及清开灵注射液治疗小儿支气管肺炎的疗效。方法 120例支气管肺炎患儿根据入院次序分为炎琥宁组、痰热清组、清开灵组各40例,在抗感染、止咳化痰、降温等综合治疗的基础上,炎琥宁组加用炎琥宁注射液,痰热清组加... 目的比较炎琥宁、痰热清及清开灵注射液治疗小儿支气管肺炎的疗效。方法 120例支气管肺炎患儿根据入院次序分为炎琥宁组、痰热清组、清开灵组各40例,在抗感染、止咳化痰、降温等综合治疗的基础上,炎琥宁组加用炎琥宁注射液,痰热清组加用痰热清注射液,清开灵组加用清开灵注射液,7d后观察3组患儿临床疗效。结果炎琥宁、痰热清、清开灵3组的治疗总有效率分别是97.5%(39/40)、95.0%(38/40)、80.0%(32/40),炎琥宁、痰热清两组显著高于清开灵组,差异有统计学意义(P均<0.05),炎琥宁、痰热清两组间比较差异无统计学意义(P>0.05)。炎琥宁、痰热清两组患儿症状体征消失时间及总病程均明显短于清开灵组,差异有统计学意义(P<0.05),炎琥宁、痰热清两组间差异无统计学意义(P>0.05)。3组在治疗过程中未发现不良反应。结论炎琥宁、痰热清注射液治疗小儿支气管肺炎疗效优于清开灵注射液。 展开更多
关键词 支气管肺炎 炎琥宁注射液/治疗应用 痰热清注射液/治疗应用 清开灵注射液/治 疗应用 儿童 学龄前
下载PDF
Qingkailing injection for the treatment of acute stroke: a systematic review and Meta-analysis 被引量:9
2
作者 JiaruiWu Xiaomeng Zhang Bing Zhang 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2014年第2期131-139,共9页
OBJECTIVE: To evaluate systematically the clinical efficacy and safety of Qingkailing (QKL) injection in the treatment of acute stroke. METHODS: Searches for randomized controlled trials into acute stroke treated ... OBJECTIVE: To evaluate systematically the clinical efficacy and safety of Qingkailing (QKL) injection in the treatment of acute stroke. METHODS: Searches for randomized controlled trials into acute stroke treated with QKL injection were performed in the China National Knowledge Infrastructure Database, China Science and Technology Journal Database, Wan fang Database, Chinese Biomedical Literature Database, PubMed and Cochrane Library, from January 1979 to March 2013. Two reviewers independently retrieved the RCTs and extracted the information. The Cochrane risk of bias method was used to assess the quality of the included studies, and a Meta-analysis was conducted with Review Manager 5.2 software. RESULTS: A total of 13 studies with 1110 participants were included. The quality of the studies was generally low. The Meta-analysis indicated that the combined use of QKL and Western Medicine was significantly superior to control group therapy in terms of the total effective rate. The relative risk (RR) in the acute cerebral hemorrhage (ACH) sub-group was 1.17 [95% confidence interval (CI) (1.08, 1.26), P=0.0001]. In the acute cerebral infarction (ACI) sub-group, RR was 1.27 [9.5% CI (1.14, 1.42), P〈0.0001], and in the ACH and ACI mixed sub-group, RR was 1.34 [95% CI (1.20,1.50),P〈0.00001]. Additionally, QKL promoted the absorption of hematoma [mean difference (MD)= - 3.73, 95%0 ( - 4.48, - 2.98), P〈0.000 01], decreased neurological damage in ACI [MD= - 5.60, 95% CI ( - 8.50, - 2.70), P=0.0002] and ACH [MD= 4.08, 95% CI ( - 8.00, 0.16), P=0.04], promoted the recovery of awareness [RR=1.56, 95% CI (1.09, 2.21), P=0.01] and reduced the whole blood viscosity coefficient [MD=- 0.75, 95% CI ( - 1.47, - 0.03), P=0.04]. There were no adverse drug reactions reported in the included studies. CONCLUSION" Based on this systematic review, QKL combined with conventional therapy was effective compared with control treatment. However, because the articles used in the study were not of high quality, further studies should be conducted into the efficacy and safety of QKL in treating acute stroke. 展开更多
关键词 Qingkailing injection STROKE Acutecerebrovascular disease META-ANALYSIS Rando-mized controlled trials REVIEW
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部